Does CYP3A5 polymorphism influence everolimus intestinal and hepatic metabolism?

被引：0
|
作者：
Rouguieg-Malki, K.
Picard, N.
Marquet, P.
机构：
[1] Univ Limoges, UMR S 850, INSERM, Limoges, France
[2] CHU Limoges, Limoges, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
346
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [1] No effect of CYP3A5 polymorphism on intestinal or hepatic metabolism of midazolam
    Tomalik-Scharte, D
    Doroshyenko, O
    Kirchheiner, J
    Jetter, A
    Lazar, A
    Klaassen, T
    Frank, D
    Fuhr, U
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (09) : 721 - 721
  • [2] No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam
    Tomalik-Scharte, D.
    Doroshyenko, O.
    Kirchheiner, J.
    Jetter, A.
    Lazar, A.
    Klaassen, T.
    Frank, D.
    Wyen, C.
    Faetkenheuer, G.
    Fuhr, U.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (10) : 1033 - 1035
  • [3] No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam
    D. Tomalik-Scharte
    O. Doroshyenko
    J. Kirchheiner
    A. Jetter
    A. Lazar
    T. Klaassen
    D. Frank
    C. Wyen
    G. Fätkenheuer
    U. Fuhr
    European Journal of Clinical Pharmacology, 2008, 64 : 1033 - 1035
  • [4] CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients
    Picard, Nicolas
    Rouguieg-Malki, Koukeb
    Kamar, Nassim
    Rostaing, Lionel
    Marquet, Pierre
    TRANSPLANTATION, 2011, 91 (06) : 652 - 656
  • [5] Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism
    Lin, YS
    Dowling, ALS
    Quigley, SD
    Farin, FM
    Zhang, J
    Lamba, J
    Schuetz, EG
    Thummel, KE
    MOLECULAR PHARMACOLOGY, 2002, 62 (01) : 162 - 172
  • [6] Influence of CYP3A5 Polymorphism on the Pharmacokinetics of Psychiatric Drugs
    Ragia, Georgia
    Dahl, Marja-Liisa
    Manolopoulos, Vangelis G.
    CURRENT DRUG METABOLISM, 2016, 17 (03) : 227 - 236
  • [7] CYP3A5 genotype influences differently the hepatic clearance of tacrolimus, sirolimus and everolimus
    Picard, Nicolas
    Djebli, Nassim
    Sauvage, Francois-Ludovic
    Marquet, Pierre
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 544 - 544
  • [8] Does the CYP3A5*3 polymorphism affect in vivo drug elimination?
    Thummel, KE
    PHARMACOGENETICS, 2003, 13 (10): : 585 - 587
  • [9] Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients
    Chu, Xiao-man
    Hao, Hai-ping
    Wang, Guang-ji
    Guo, Lian-qing
    Min, Pei-qing
    ACTA PHARMACOLOGICA SINICA, 2006, 27 (11) : 1504 - 1508
  • [10] Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients
    Xiao-man Chu
    Hai-ping Hao
    Guang-ji Wang
    Lian-qing Guo
    Pei-qing Min
    Acta Pharmacologica Sinica, 2006, 27 : 1504 - 1508
12345